gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Photodynamic therapy: 4 years of experience

Meeting Abstract

Suche in Medline nach

  • corresponding author M. Rauber - Augenklinik Sulzbach der Bundesknappschaft
  • F. Binkle - Augenklinik Sulzbach der Bundesknappschaft
  • K. Kremp - Augenklinik Sulzbach der Bundesknappschaft
  • U. Mester - Augenklinik Sulzbach der Bundesknappschaft

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogFR.03.05

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dog2004/04dog181.shtml

Veröffentlicht: 22. September 2004

© 2004 Rauber et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

Application of photodynamic therapy with verteporfin was done on 622 eyes over a period of 4 years. We found it necessary to focus critically on our indications and results.

Methods

Retrospective study of patient datas recorded from february 2000 to march 2004.

Results

We performed 1163 photodynamic therapies with verteporfin on 622 eyes. 70% of the patients felt their visual acuity of the treated eyes better than before. This doesn't correspond to the objective development of visual acuity: in the hughest group (439 patients with AMD) only a partial stabilisation of visual acuity could be achieved (0,15±0,12 preop. versus 0.13±0,12 postop.). 34 patients with a choroidal neovascularisation caused by pathologic myopia did better: visual acuity grew from 0,15±0,10 to 0,23±0,19, and younger myopics had the greatest gain. 12 patients had different underlying diagnosis for choroidal neovascularisation (uveitis, scars after laser treatment, angioid streaks). They reacted differently to the therapy with verteporfin: the mean visual acuity grew from 0,17±0,09 to 0,19±0,18, but patients with angioid streaks had a poor outcome. Indications for photodynamic therapy were increasingly restricted. Together with more concret guidelines for our patients we could significantly improve our results.

Conclusions

Photodynamic therapy has enriched our therapeutic arsenal. Patient's subjective jugement of the therapeutic results is better than the objective course of visual acuity. Results can be improved by improving indication and patient's guidelines.